MedPath

The Safety and Effectiveness of Zidovudine in the Treatment of Patients With Early AIDS Related Complex

Phase 3
Completed
Conditions
HIV Infections
Registration Number
NCT00001011
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

To determine the safety and usefulness of zidovudine (AZT) for the treatment of patients with early symptomatic HIV infection or early AIDS related complex (ARC). The ability of AZT to suppress HIV, to improve body defenses, and to prevent the occurrence or development of AIDS or advanced ARC is being evaluated.

In one human study, patients with AIDS or advanced ARC who received AZT had fewer life-threatening infections, improved in weight and performance, and lived longer than patients who received a placebo (inactive medication). Further studies are needed because toxic effects associated with the use of AZT were noted and the long-term effectiveness and toxicity of AZT are still unknown. It is also unknown if AZT will benefit patients with less severe HIV infections such as early ARC or PGL.

Detailed Description

In one human study, patients with AIDS or advanced ARC who received AZT had fewer life-threatening infections, improved in weight and performance, and lived longer than patients who received a placebo (inactive medication). Further studies are needed because toxic effects associated with the use of AZT were noted and the long-term effectiveness and toxicity of AZT are still unknown. It is also unknown if AZT will benefit patients with less severe HIV infections such as early ARC or PGL.

Patients accepted into the study are randomly assigned to receive either AZT or placebo. Treatment continues for a minimum of 104 weeks beyond the time the last patient enters the study. If the study medication causes toxic effects, the dose is decreased or temporarily stopped, and if the toxic effects are severe, then the medication will be stopped permanently. Participants visit the clinic every 2 weeks during the first 16 weeks and once a month thereafter. Throughout the study frequent blood samples are taken to monitor the effectiveness and safety of the treatment. AMENDED: The placebo arm has been discontinued as of August 3, 1989 and the AZT dose has been reduced.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
538
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (40)

Los Angeles County - USC Med Ctr

🇺🇸

Los Angeles, California, United States

UCLA CARE Ctr

🇺🇸

Los Angeles, California, United States

Harbor UCLA Med Ctr

🇺🇸

Torrance, California, United States

Univ of Miami School of Medicine

🇺🇸

Miami, Florida, United States

Northwestern Univ Med School

🇺🇸

Chicago, Illinois, United States

Indiana Univ Hosp

🇺🇸

Indianapolis, Indiana, United States

Johns Hopkins Hosp

🇺🇸

Baltimore, Maryland, United States

Beth Israel Deaconess - West Campus

🇺🇸

Boston, Massachusetts, United States

SUNY - Stony Brook

🇺🇸

Stony Brook, New York, United States

Univ of Minnesota

🇺🇸

Minneapolis, Minnesota, United States

Beth Israel Med Ctr / Peter Krueger Clinic

🇺🇸

New York, New York, United States

Duke Univ Med Ctr

🇺🇸

Durham, North Carolina, United States

SUNY / Erie County Med Ctr at Buffalo

🇺🇸

Buffalo, New York, United States

Univ of Washington

🇺🇸

Seattle, Washington, United States

Stanford Univ School of Medicine

🇺🇸

Stanford, California, United States

Harvard (Massachusetts Gen Hosp)

🇺🇸

Boston, Massachusetts, United States

Holmes Hosp / Univ of Cincinnati Med Ctr

🇺🇸

Cincinnati, Ohio, United States

Thomas Jefferson Univ Hosp

🇺🇸

Philadelphia, Pennsylvania, United States

Columbus Children's Hosp

🇺🇸

Columbus, Ohio, United States

Ohio State Univ Hosp Clinic

🇺🇸

Columbus, Ohio, United States

Univ of Pittsburgh Med School

🇺🇸

Pittsburgh, Pennsylvania, United States

Univ Hosp of Cleveland / Case Western Reserve Univ

🇺🇸

Cleveland, Ohio, United States

Stanford at Kaiser / Kaiser Permanente Med Ctr

🇺🇸

San Francisco, California, United States

St Louis Regional Hosp / St Louis Regional Med Ctr

🇺🇸

Saint Louis, Missouri, United States

City Hosp Ctr at Elmhurst / Mount Sinai Hosp

🇺🇸

Elmhurst, New York, United States

Cornell Univ Med Ctr

🇺🇸

New York, New York, United States

Saint Luke's - Roosevelt Hosp Ctr

🇺🇸

New York, New York, United States

Univ of Rochester Medical Center

🇺🇸

Rochester, New York, United States

Mount Sinai Med Ctr

🇺🇸

New York, New York, United States

SUNY / State Univ of New York

🇺🇸

Syracuse, New York, United States

Palo Alto Veterans Adm Med Ctr / Stanford Univ

🇺🇸

Palo Alto, California, United States

Univ of California / San Diego Treatment Ctr

🇺🇸

San Diego, California, United States

George Washington Univ Med Ctr

🇺🇸

Washington, District of Columbia, United States

Bellevue Hosp / New York Univ Med Ctr

🇺🇸

New York, New York, United States

Julio Arroyo

🇺🇸

West Columbia, South Carolina, United States

Bronx Municipal Hosp Ctr/Jacobi Med Ctr

🇺🇸

Bronx, New York, United States

Jack Weiler Hosp / Bronx Municipal Hosp

🇺🇸

Bronx, New York, United States

Montefiore Med Ctr / Bronx Municipal Hosp

🇺🇸

Bronx, New York, United States

Bronx Veterans Administration / Mount Sinai Hosp

🇺🇸

Bronx, New York, United States

Univ of North Carolina

🇺🇸

Chapel Hill, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath